Get the Stockscreener App
37.37
3.29%
-1.27
After Hours:
37.50
0.13
+0.35%
Lenz Therapeutics Inc stock is traded at $37.37, with a volume of 629.07K.
It is down -3.29% in the last 24 hours and up +18.18% over the past month.
LENZ Therapeutics Inc is a late-stage biopharmaceutical company focused on developing and commercializing therapies to improve vision and developing ophthalmic pharmaceutical products.. Its initial focus is the treatment of presbyopia, the inevitable loss of near vision that impacts the daily lives of nearly all people over 45.
See More
Previous Close:
$38.64
Open:
$38.525
24h Volume:
629.07K
Relative Volume:
1.41
Market Cap:
$1.07B
Revenue:
-
Net Income/Loss:
$-69.47M
P/E Ratio:
-6.6764
EPS:
-5.5973
Net Cash Flow:
$-73.92M
1W Performance:
-3.04%
1M Performance:
+18.18%
6M Performance:
+75.53%
1Y Performance:
+69.86%
1-Day Range:
$36.81
$39.50
1-Week Range:
$36.81
$41.26
52-Week Range:
$16.54
$41.70
Lenz Therapeutics Inc Stock (LENZ) Company Profile
Name
Lenz Therapeutics Inc
Sector
Industry
Phone
858-925-7000
Address
201 LOMAS SANTA FE DRIVE, SUITE 300, SOLANA BEACH
Compare LENZ with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LENZ
Lenz Therapeutics Inc
|
37.37 | 1.10B | 0 | -69.47M | -73.92M | -5.5973 |
|
VRTX
Vertex Pharmaceuticals Inc
|
389.08 | 99.27B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
586.96 | 62.28B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.18 | 59.14B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
707.96 | 43.34B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
300.14 | 36.72B | 3.81B | -644.79M | -669.77M | -6.24 |
Lenz Therapeutics Inc Stock (LENZ) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-14-25 | Resumed | Piper Sandler | Overweight |
| Mar-18-25 | Initiated | TD Cowen | Buy |
| Sep-27-24 | Initiated | Raymond James | Outperform |
| Aug-12-24 | Initiated | H.C. Wainwright | Buy |
| Apr-15-24 | Initiated | Leerink Partners | Outperform |
| Apr-15-24 | Initiated | William Blair | Outperform |
| Apr-10-24 | Initiated | Citigroup | Buy |
| Mar-27-24 | Initiated | Piper Sandler | Overweight |
| Feb-23-23 | Downgrade | BofA Securities | Neutral → Underperform |
| Feb-23-23 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Feb-23-23 | Downgrade | Cowen | Outperform → Market Perform |
| Jan-25-23 | Downgrade | BTIG Research | Buy → Neutral |
| Jan-18-23 | Downgrade | BofA Securities | Buy → Neutral |
| Jan-06-23 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Jan-06-23 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Sep-15-22 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-17-22 | Initiated | BMO Capital Markets | Outperform |
| Apr-14-22 | Initiated | BTIG Research | Buy |
| Mar-22-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Feb-18-22 | Initiated | RBC Capital Mkts | Sector Perform |
| Jul-20-21 | Initiated | Morgan Stanley | Overweight |
| Jul-20-21 | Initiated | SVB Leerink | Outperform |
View All
Lenz Therapeutics Inc Stock (LENZ) Latest News
How institutional ownership impacts LENZ Therapeutics Inc. stock2025 EndofYear Setup & Verified Chart Pattern Signals - Newser
Should you hold or exit LENZ Therapeutics Inc. nowJuly 2025 Macro Moves & Community Supported Trade Ideas - Newser
Why LENZ Therapeutics Inc. is moving today2025 EndofYear Setup & Safe Entry Zone Tips - Newser
LENZ Therapeutics Inc. stock outlook for YEAR2025 Valuation Update & Reliable Volume Spike Trade Alerts - Newser
Has LENZ Therapeutics Inc. found a price floor2025 Market Outlook & Momentum Based Trading Ideas - Newser
Relative strength of LENZ Therapeutics Inc. in sector analysisShort Setup & Capital Efficient Trade Techniques - Newser
What the charts say about LENZ Therapeutics Inc. todayMarket Growth Review & Fast Exit and Entry Trade Guides - Newser
Using data tools to time your LENZ Therapeutics Inc. exitPortfolio Gains Report & Consistent Profit Trade Alerts - Newser
What makes LENZ Therapeutics Inc. stock price move sharplyPortfolio Value Summary & AI Based Buy/Sell Signal Reports - Newser
Detecting support and resistance levels for LENZ Therapeutics Inc.July 2025 Summary & Low Risk High Reward Ideas - Newser
Trend analysis for LENZ Therapeutics Inc. this weekWeekly Stock Report & Safe Swing Trade Setups - Newser
Real time breakdown of LENZ Therapeutics Inc. stock performanceGlobal Markets & Stepwise Trade Execution Plans - Newser
Using data models to predict LENZ Therapeutics Inc. stock movementWeekly Gains Report & Capital Efficiency Focused Strategies - Newser
Investors Hope for Bounce in LENZ Therapeutics Inc. After Selloff getLinesFromResByArray error: size == 0 - sisain.net
Full technical analysis of LENZ Therapeutics Inc. stock2025 Risk Factors & AI Forecasted Entry and Exit Points - Newser
LENZ Therapeutics Inc.’s volatility index tracking explainedJuly 2025 Update & High Yield Stock Recommendations - Newser
Analyzing LENZ Therapeutics Inc. with risk reward ratio chartsWeekly Risk Report & Fast Exit Strategy with Risk Control - Newser
How to build a dashboard for LENZ Therapeutics Inc. stock2025 Retail Activity & Low Risk Entry Point Tips - Newser
What MACD and RSI say about LENZ Therapeutics Inc.Market Sentiment Summary & Free Weekly Chart Analysis and Trade Guides - Newser
How to manage a losing position in LENZ Therapeutics Inc.Trade Risk Assessment & AI Powered Market Entry Ideas - Newser
LENZ Therapeutics to Present VIZZ at Upcoming Investor and Medical Conferences. - AInvest
First FDA-Approved Aceclidine Eye Drops: LENZ Therapeutics to Present VIZZ Data at Multiple Fall Conferences - Stock Titan
How much upside does LENZ Therapeutics Inc. haveTrade Signal Summary & Daily Stock Trend Watchlist - sundaytimes.kr
Will LENZ Therapeutics Inc. stock recover after recent drop2025 Breakouts & Breakdowns & Risk Managed Investment Strategies - Newser
Will LENZ Therapeutics Inc. benefit from macro trendsForecast Cut & Growth-Oriented Investment Plans - Newser
Has LENZ Therapeutics Inc. Stock Ever Crashed Historical Volatility Review2025 Risk Factors & Growth Focused Investment Plans - Newser
LENZ Therapeutics stock price target raised to $56 from $48 at H.C. Wainwright By Investing.com - Investing.com Nigeria
LENZ Therapeutics stock price target raised to $56 from $48 at H.C. Wainwright - Investing.com
LENZ Therapeutics Inc. Stocks Attracting Dip BuyersJuly 2025 Rallies & High Conviction Buy Zone Alerts - 더경남뉴스
LENZ Therapeutics' Vizz Approval Sets Stage for Commercial Potential - AInvest
Will FDA Approval of Vizz Eye Drops Change LENZ Therapeutics' (LENZ) Narrative? - Yahoo Finance
What high frequency data says about LENZ Therapeutics Inc.2025 Top Decliners & Step-by-Step Swing Trade Plans - Newser
News impact scoring models applied to LENZ Therapeutics Inc.Market Sentiment Report & Real-Time Buy Signal Notifications - Newser
Does LENZ Therapeutics Inc. qualify in momentum factor screeningPortfolio Return Summary & Short-Term Trading Alerts - Newser
Lenz Therapeutics Inc Stock (LENZ) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.98%
8.06%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):